Journal
MUCOSAL IMMUNOLOGY
Volume 7, Issue 1, Pages 6-19Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mi.2013.73
Keywords
-
Categories
Funding
- German Research Council DFG
- DFG SchwerpunktprogrammMicrobiota
- KFO CEDER
- German Cancer Aid
- Comprehensive Cancer Center CCC-EMN
- IZKF Erlangen
Ask authors/readers for more resources
Healing of the inflamed mucosa (mucosal healing) is an emerging new goal for therapy and predicts clinical remission and resection-free survival in inflammatory bowel diseases (IBDs). The era of antitumor necrosis factor (TNF) antibody therapy was a remarkable progress in IBD therapy and anti- TNF agents led to mucosal healing in a subgroup of IBD patients; however, many patients do not respond to anti-TNF treatment highlighting the relevance of finding new targets for therapy of IBD. In particular, current studies are addressing the role of other anticytokine agents including antibodies against interleukin (IL)-6R, IL-13, and IL-12/IL-23 as well as new anti-inflammatory concepts (regulatory T cell therapy, Smad7 antisense, Jak inhibition, Toll-like receptor 9 stimulation, worm eggs). In addition, blockade of T-cell homing via the integrins alpha(4)beta(7) and the addressin mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) emerges as a promising new approach for IBD therapy. Here, new approaches for achieving mucosal healing are discussed as well as their implications for future therapy of IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available